Alisertib
Recurrent Rectal Cancer
University of California, DavisSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
70 Active assets in the Recurrent Rectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Sun Yat-sen University | Phase 4 | BBB |
FLUOROURACILUM Seoul National University Hospital | Phase 3 | BBB |
Eloxatin Sun Yat-sen University | Phase 3 | BBB |
Irinotecan Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | BB |
Capecitabine Tao Zhang | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Alisertib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →